Patent Oppositions in metabolic drugs industry

Explore the competitive field of metabolic drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in metabolic drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the metabolic drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the metabolic drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Jul 9, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Sotorasib Dosing RegimenAMGENMay 26, 2026BOTTI & FERRARI
Beta-1,3'-Galactosyllactose For The Treatment Of Gut Barrier Function DiseasesNUTRICIAMay 19, 2026NESTLE
Low Calorie Food Preparation For The Nutrition Of Cancer PatientsFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORIMay 19, 2026L NUTRA
Bacteriotherapy For Clostridium Difficile ColitisREBIOTIXMay 19, 2026PLASSERAUD
Neutralization Of Inhibitory Pathways In LymphocytesINNATE PHARMAMay 13, 2026STRAWMAN
Methods For Treating HyperphenylalaninemiaPTC THERAPEUTICS MPMay 12, 2026ALFRED E TIEFENBACHER
Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECAMay 12, 2026SANDOZ
Methods For Treating HyperphenylalaninemiaPTC THERAPEUTICS MPMay 10, 2026SYNTHON
Methods For Treating Nasal Polyposis By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSMay 6, 2026ENGELHARD
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKMay 6, 2026UNIVERSAL FARMA

To stay ahead in the competitive metabolic drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the metabolic drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Jul 9, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS26
Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY24
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM19
Aug 6, 2025Use Of Long-Acting Glp-1 PeptidesNOVO NORDISK18
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE17
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI MATURE15
Jan 7, 2026Formulations Of EnzalutamideASTELLAS PHARMA14
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB11
Dec 18, 2024Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIM11